Last reviewed · How we verify
NCT06939049: SISTEMA
Development of New Methodologies and Innovative Tools for the diagnoSi and Therapeutic Treatment of uMAni Epithelial Tumors
trial in Cancer Risk in 250 participants. Currently enrolling.
31 July 2021
Quick facts
| Lead sponsor | ASL Lecce |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 2 May 2017 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Italy |
Conditions studied
- Cancer Risk — all drugs for Cancer Risk →
- Breast Cancer Risk — all drugs for Breast Cancer Risk →
- Lung Cancer (NSCLC) — all drugs for Lung Cancer (NSCLC) →
Sponsor
ASL Lecce
Who can join
18 and older, any sex, with Cancer Risk or Breast Cancer Risk. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of the SISTEMA project is to develop non-invasive diagnostic tests for the detection and quantification in blood of markers of Mesenchymal Epithelial Transition, a mechanism that characterises certain types of cancer such as breast and lung cancer. Cancer is still one of the leading causes of death in Western countries. In 2014, there were an estimated 1,665,540 new cancer cases and 585,720 deaths in the United States alone. The World Health Organisation (WHO) and Eurostat predict 1,323,600 deaths in Europe, a figure slightly down on previous statistics but still underlining the existence and seriousness of the problem. It is no coincidence that cancer is one of the main areas of investment in the European Horizon 2020 programme. In recent years, the hypothesis that the process of carcinogenesis is driven by the activation of a particular panel of genes/proteins that enable cancer cells to acquire malignant characteristics has become increasingly popular. This process goes by the name Epithelial Mesenchymal Transition (EMT) and characterises all human epithelial tumours. This process allows epithelial tumour cells to acquire mesenchymal characteristics giving them stem, invasive, and chemoresistant properties.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06939049
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Risk
Currently open trials in the same condition.
- NCT07121972 — Mirai-MRI: Validation of AI Models for Breast Cancer Risk · NA · recruiting
- NCT06804395 — CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management · recruiting
- NCT06864260 — Cancer PRevention Through Enhanced EnvironMenT · NA · active not recruiting
- NCT05463796 — InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer · recruiting
- NCT06653478 — Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagn · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06939049 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ASL Lecce
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06939049.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing